Total Payments
$55,400
2024 Payments
$3,485
Companies
78
Transactions
1,483
Medicare Patients
8,358
Medicare Billing
$1.0M
Payment Breakdown by Category
Research$28,940 (52.2%)
Food & Beverage$24,930 (45.0%)
Education$575.10 (1.0%)
Travel$407.03 (0.7%)
Consulting$300.00 (0.5%)
Other$248.17 (0.4%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $28,940 | 9 | 52.2% |
| Food and Beverage | $24,930 | 1,427 | 45.0% |
| Education | $575.10 | 28 | 1.0% |
| Travel and Lodging | $407.03 | 2 | 0.7% |
| Consulting Fee | $300.00 | 2 | 0.5% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $248.17 | 15 | 0.4% |
Payments by Type
Research
$28,940
9 transactions
General
$26,460
1,474 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| ACADIA Pharmaceuticals Inc | $13,945 | 120 | $0 (2024) |
| Eli Lilly and Company | $9,494 | 3 | $0 (2018) |
| Biogen, Inc. | $8,735 | 121 | $0 (2024) |
| Teva Pharmaceuticals USA, Inc. | $1,638 | 102 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $1,471 | 91 | $0 (2024) |
| ABBVIE INC. | $1,386 | 97 | $0 (2024) |
| Supernus Pharmaceuticals, Inc. | $1,131 | 91 | $0 (2022) |
| GENZYME CORPORATION | $994.82 | 49 | $0 (2023) |
| Allergan, Inc. | $991.17 | 48 | $0 (2021) |
| EMD Serono, Inc. | $969.57 | 42 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $3,485 | 173 | ABBVIE INC. ($377.92) |
| 2023 | $3,765 | 191 | Biogen, Inc. ($404.94) |
| 2022 | $3,479 | 176 | ABBVIE INC. ($366.95) |
| 2021 | $3,281 | 175 | Biogen, Inc. ($530.01) |
| 2020 | $2,554 | 165 | Novartis Pharmaceuticals Corporation ($275.96) |
| 2019 | $10,320 | 225 | Biogen, Inc. ($6,696) |
| 2018 | $24,096 | 214 | ACADIA Pharmaceuticals Inc ($12,737) |
| 2017 | $4,419 | 164 | Eli Lilly and Company ($1,723) |
All Payment Transactions
1,483 individual payment records from CMS Open Payments — Page 1 of 60
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/18/2024 | Teva Pharmaceuticals USA, Inc. | Austedo XR (Drug) | Food and Beverage | In-kind items and services | $22.92 | General |
| Category: Central Nervous System | ||||||
| 12/16/2024 | EMD Serono, Inc. | Mavenclad (Drug) | Food and Beverage | Cash or cash equivalent | $22.69 | General |
| Category: Neurology | ||||||
| 12/12/2024 | AstraZeneca Pharmaceuticals LP | WAINUA (Drug) | Food and Beverage | In-kind items and services | $16.51 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 12/12/2024 | ABBVIE INC. | QULIPTA (Drug), UBRELVY | Food and Beverage | In-kind items and services | $7.02 | General |
| Category: NEUROSCIENCE | ||||||
| 12/12/2024 | ABBVIE INC. | QULIPTA (Drug), UBRELVY | Food and Beverage | In-kind items and services | $0.92 | General |
| Category: NEUROSCIENCE | ||||||
| 12/11/2024 | Biogen, Inc. | VUMERITY (Drug) | Food and Beverage | In-kind items and services | $18.99 | General |
| Category: Neurology | ||||||
| 12/09/2024 | Eisai Inc. | Leqembi (Drug) | Food and Beverage | In-kind items and services | $16.11 | General |
| Category: Neurology | ||||||
| 12/05/2024 | ABBVIE INC. | UBRELVY (Drug), QULIPTA | Food and Beverage | In-kind items and services | $10.23 | General |
| Category: NEUROSCIENCE | ||||||
| 12/02/2024 | PFIZER INC. | NURTEC ODT (Drug), ZAVZPRET | Food and Beverage | In-kind items and services | $17.18 | General |
| Category: PAIN | ||||||
| 12/01/2024 | Lundbeck LLC | VYEPTI (Biological) | Food and Beverage | Cash or cash equivalent | $28.46 | General |
| Category: NEUROLOGY | ||||||
| 11/27/2024 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Food and Beverage | In-kind items and services | $18.10 | General |
| Category: Neuropsychiatry | ||||||
| 11/26/2024 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Food and Beverage | In-kind items and services | $6.91 | General |
| Category: Neuropsychiatry | ||||||
| 11/25/2024 | PFIZER INC. | NURTEC ODT (Drug), ZAVZPRET | Food and Beverage | In-kind items and services | $23.97 | General |
| Category: PAIN | ||||||
| 11/20/2024 | Kyowa Kirin, Inc. | Nourianz (Drug) | Food and Beverage | In-kind items and services | $26.62 | General |
| Category: Adenosine A2A Receptors | ||||||
| 11/18/2024 | Lilly USA, LLC | KISUNLA (Drug) | Food and Beverage | In-kind items and services | $23.24 | General |
| Category: Neuroscience | ||||||
| 11/14/2024 | Kyowa Kirin, Inc. | Nourianz (Drug) | Food and Beverage | In-kind items and services | $28.50 | General |
| Category: Adenosine A2A Receptors | ||||||
| 11/14/2024 | Amneal Pharmaceuticals LLC | CREXONT (Drug) | Food and Beverage | In-kind items and services | $15.38 | General |
| Category: NEUROLOGY | ||||||
| 11/13/2024 | EMD Serono, Inc. | — | Food and Beverage | Cash or cash equivalent | $18.28 | General |
| 11/12/2024 | Biogen, Inc. | TYSABRI (Biological), VUMERITY | Food and Beverage | In-kind items and services | $22.57 | General |
| Category: Neurology | ||||||
| 11/07/2024 | Celgene Corporation | ZEPOSIA (Drug) | Food and Beverage | Cash or cash equivalent | $20.51 | General |
| Category: Neuroscience | ||||||
| 11/05/2024 | ABBVIE INC. | QULIPTA (Drug) | Food and Beverage | In-kind items and services | $25.05 | General |
| Category: NEUROSCIENCE | ||||||
| 11/05/2024 | Novartis Pharmaceuticals Corporation | KESIMPTA (Drug) | Food and Beverage | In-kind items and services | $14.43 | General |
| Category: Neurology | ||||||
| 11/01/2024 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Food and Beverage | In-kind items and services | $22.54 | General |
| Category: Neuropsychiatry | ||||||
| 10/29/2024 | Biogen, Inc. | VUMERITY (Drug) | Food and Beverage | In-kind items and services | $20.59 | General |
| Category: Neurology | ||||||
| 10/28/2024 | ABBVIE INC. | QULIPTA (Drug), UBRELVY | Food and Beverage | In-kind items and services | $12.44 | General |
| Category: NEUROSCIENCE | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| ACP-103-045 | ACADIA Pharmaceuticals Inc | $12,545 | 3 |
| A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF LY2951742 IN PATIENTS WITH CHRONIC MIGRAINE - THE REGAIN STUDY | Eli Lilly and Company | $9,494 | 3 |
| Dimethyl Fumarate (DMF) Observational Study | Biogen, Inc. | $5,495 | 1 |
| Effect of BG00012 on Lymphocyte Subsets and Immunoglobulins in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS). | Biogen, Inc. | $930.00 | 1 |
| A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF MULTIPLE DOSING REGIMENS OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE | Allergan Inc. | $476.19 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 11 | 1,789 | 2,002 | $739,262 | $215,840 |
| 2022 | 10 | 1,749 | 1,866 | $728,535 | $219,087 |
| 2021 | 10 | 2,130 | 2,211 | $825,517 | $269,924 |
| 2020 | 13 | 2,690 | 3,028 | $625,181 | $315,343 |
Total Patients
8,358
Total Services
9,107
Medicare Billing
$1.0M
Procedure Codes
44
All Medicare Procedures & Services
44 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 436 | 560 | $142,777 | $47,702 | 33.4% |
| 93886 | Complete ultrasound of within the brain blood flow | Office | 2023 | 176 | 177 | $112,004 | $32,438 | 29.0% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 404 | 466 | $80,523 | $27,534 | 34.2% |
| 95819 | Measurement of brain wave activity (eeg), awake and asleep | Office | 2023 | 81 | 82 | $79,294 | $25,962 | 32.7% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 206 | 206 | $80,958 | $24,316 | 30.0% |
| 93880 | Ultrasound of both sides of head and neck blood flow | Office | 2023 | 174 | 175 | $87,589 | $19,859 | 22.7% |
| 95911 | Nerve conduction, 9-10 studies | Office | 2023 | 101 | 102 | $79,083 | $15,509 | 19.6% |
| 95886 | Needle measurement of electrical activity in arm or leg muscles, complete study | Office | 2023 | 129 | 150 | $32,550 | $10,961 | 33.7% |
| 95912 | Nerve conduction, 11-12 studies | Office | 2023 | 51 | 52 | $32,451 | $9,245 | 28.5% |
| 96132 | Evaluation of neuropsychological test, first hour | Office | 2023 | 19 | 20 | $10,400 | $2,016 | 19.4% |
| 96138 | Administration of psychological or neuropsychological test by technician, first 30 minutes | Office | 2023 | 12 | 12 | $1,632 | $298.68 | 18.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 395 | 464 | $118,598 | $41,648 | 35.1% |
| 93886 | Complete ultrasound of within the brain blood flow | Office | 2022 | 213 | 215 | $135,683 | $41,117 | 30.3% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 225 | 225 | $88,425 | $26,393 | 29.8% |
| 95819 | Measurement of brain wave activity (eeg), awake and asleep | Office | 2022 | 77 | 77 | $74,459 | $25,785 | 34.6% |
| 93880 | Ultrasound of both sides of head and neck blood flow | Office | 2022 | 208 | 210 | $104,775 | $24,461 | 23.3% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 343 | 374 | $64,983 | $24,287 | 37.4% |
| 95911 | Nerve conduction, 9-10 studies | Office | 2022 | 95 | 95 | $73,522 | $14,319 | 19.5% |
| 95886 | Needle measurement of electrical activity in arm or leg muscles, complete study | Office | 2022 | 131 | 144 | $30,996 | $10,877 | 35.1% |
| 95912 | Nerve conduction, 11-12 studies | Office | 2022 | 50 | 50 | $30,663 | $8,813 | 28.7% |
| 93306 | Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | Office | 2022 | 12 | 12 | $6,432 | $1,388 | 21.6% |
| 93886 | Ultrasound scanning of head and neck vessel blood flow (inside the brain) | Office | 2021 | 282 | 290 | $157,529 | $54,841 | 34.8% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 386 | 386 | $136,357 | $45,398 | 33.3% |
| 95819 | Measurement and recording of brain wave (eeg) activity, awake and asleep | Office | 2021 | 104 | 104 | $88,249 | $34,516 | 39.1% |
| 93880 | Ultrasound scanning of blood flow (outside the brain) on both sides of head and neck | Office | 2021 | 268 | 275 | $116,591 | $32,954 | 28.3% |
About Dr. Bogdan Gheorghiu, M.D
Dr. Bogdan Gheorghiu, M.D is a Neurology healthcare provider based in Spartanburg, South Carolina. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 09/25/2005. The National Provider Identifier (NPI) number assigned to this provider is 1902892904.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Bogdan Gheorghiu, M.D has received a total of $55,400 in payments from pharmaceutical and medical device companies, with $3,485 received in 2024. These payments were reported across 1,483 transactions from 78 companies. The most common payment nature is "" ($28,940).
As a Medicare-enrolled provider, Gheorghiu has provided services to 8,358 Medicare beneficiaries, totaling 9,107 services with total Medicare billing of $1.0M. Data is available for 4 years (2020–2023), covering 44 distinct procedure/service records.
Ad
Practice Information
- Specialty Neurology
- Other Specialties Neurology, Neurology
- Location Spartanburg, SC
- Active Since 09/25/2005
- Last Updated 02/01/2023
- Taxonomy Code 2084N0400X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1902892904
Products in Payments
- NUPLAZID (Drug) $13,945
- TECFIDERA (Drug) $6,965
- TYSABRI (Biological) $1,202
- TROKENDI XR (Drug) $1,076
- VNS Therapy (Device) $783.76
- AUBAGIO (Drug) $716.06
- NURTEC ODT (Drug) $666.60
- ACTHAR (Biological) $654.00
- QULIPTA (Drug) $651.33
- APTIOM (Drug) $633.60
- EMGALITY (Drug) $582.42
- Aimovig (Biological) $565.56
- INGREZZA (Drug) $561.08
- OCREVUS (Biological) $493.19
- AUSTEDO (Drug) $483.70
- KESIMPTA (Drug) $441.74
- UBRELVY (Drug) $429.13
- Fycompa (Drug) $401.62
- VYEPTI (Biological) $358.90
- AIMOVIG (Biological) $354.30
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Neurology Doctors in Spartanburg
Dr. Juliette Saad, Md, MD
Neurology — Payments: $41,094
Neurology $41,094
Carol Kooistra, Md, MD
Neurology — Payments: $28,936
Neurology $28,936
Dr. Gonzalo Pares, M.d, M.D
Neurology — Payments: $10,042
Neurology $10,042
Tonya Frazier, Md, MD
Neurology — Payments: $3,646
Neurology $3,646
Andrea Gil Guevara, M.d, M.D
Neurology — Payments: $2,382
Neurology $2,382
Rowena Desailly-Chanson, Md, MD
Neurology — Payments: $660.38
Neurology $660.38